Rahul S Vedula1, R Coleman Lindsley2. 1. Dana-Farber Cancer Institute, 450 Brookline Ave., DA-530C, Boston, MA, 02115, USA. 2. Dana-Farber Cancer Institute, 450 Brookline Ave., DA-530C, Boston, MA, 02115, USA. coleman_lindsley@dfci.harvard.edu.
Abstract
PURPOSE OF REVIEW: Assessment of measurable residual disease (MRD) after treatment can identify patients with acute myeloid leukemia (AML) that are at high risk of poor outcomes. However, there is no consensus yet regarding a standardized approach to measuring MRD that is most clinically meaningful. We review multiparameter flow cytometry (MFC) and reverse transcriptase polymerase chain reaction (RT-PCR), and discuss a framework for assessing remission MRD using next-generation sequencing (NGS). RECENT FINDINGS: MFC and RT-PCR may not fully capitalize on the major advances that have been made in characterizing the genetic landscape of AML, which has offered insight into the biological and clinical implications of clonal genetic architecture. NGS has increasingly been shown to provide a qualitative and quantitative assessment of MRD with significant prognostic implications. The assessment of clonal architecture by NGS may complement or extend existing approaches for MRD monitoring. Long-term serial monitoring of diagnostic, remission, and relapse samples with clinical correlation will need to be performed in order to determine the impact of various MRD patterns using this technique.
PURPOSE OF REVIEW: Assessment of measurable residual disease (MRD) after treatment can identify patients with acute myeloid leukemia (AML) that are at high risk of poor outcomes. However, there is no consensus yet regarding a standardized approach to measuring MRD that is most clinically meaningful. We review multiparameter flow cytometry (MFC) and reverse transcriptase polymerase chain reaction (RT-PCR), and discuss a framework for assessing remission MRD using next-generation sequencing (NGS). RECENT FINDINGS: MFC and RT-PCR may not fully capitalize on the major advances that have been made in characterizing the genetic landscape of AML, which has offered insight into the biological and clinical implications of clonal genetic architecture. NGS has increasingly been shown to provide a qualitative and quantitative assessment of MRD with significant prognostic implications. The assessment of clonal architecture by NGS may complement or extend existing approaches for MRD monitoring. Long-term serial monitoring of diagnostic, remission, and relapse samples with clinical correlation will need to be performed in order to determine the impact of various MRD patterns using this technique.
Authors: David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert Journal: Blood Date: 2015-04-30 Impact factor: 22.113
Authors: M R Baer; C C Stewart; R K Dodge; G Leget; N Sulé; K Mrózek; C A Schiffer; B L Powell; J E Kolitz; J O Moore; R M Stone; F R Davey; A J Carroll; R A Larson; C D Bloomfield Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: Richard M Stone; Emanuele Mazzola; Donna Neuberg; Steven L Allen; Arnaud Pigneux; Robert K Stuart; Meir Wetzler; David Rizzieri; Harry P Erba; Lloyd Damon; Jun-Ho Jang; Martin S Tallman; Krzysztof Warzocha; Tamás Masszi; Mikkael A Sekeres; Miklos Egyed; Heinz-August Horst; Dominik Selleslag; Scott R Solomon; Parameswaran Venugopal; Ante S Lundberg; Bayard Powell Journal: J Clin Oncol Date: 2015-03-02 Impact factor: 44.544
Authors: R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert Journal: Blood Date: 2014-12-30 Impact factor: 22.113
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: D Diverio; P P Pandolfi; A Biondi; G Avvisati; M C Petti; F Mandelli; G Pelicci; F Lo Coco Journal: Blood Date: 1993-12-15 Impact factor: 22.113
Authors: Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell Journal: Blood Date: 2013-09-12 Impact factor: 22.113